Jade Biosciences, Inc.
Jade Biosciences, Inc. (Nasdaq: JBIO) is a clinical-stage biopharmaceutical company developing biologic therapies for autoimmune diseases. Its lead candidate, JADE101, is a monoclonal antibody targeting APRIL, initially being developed for IgA nephropathy; the company began a Phase 1 trial in healthy volunteers in… From the company’s description.
In fiscal 2025, Jade Biosciences, Inc. reported a net loss of $127.41M. Operations used $94.69M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Jade Biosciences, Inc. does
In the company’s own words
Jade Biosciences, Inc. (Nasdaq: JBIO) is a clinical-stage biopharmaceutical company developing biologic therapies for autoimmune diseases. Its lead candidate, JADE101, is a monoclonal antibody targeting APRIL, initially being developed for IgA nephropathy; the company began a Phase 1 trial in healthy volunteers in August 2025. JADE201 targets BAFF-R and is designed to deplete B cells and block BAFF signaling; a Phase 1 trial in rheumatoid arthritis patients is planned. JADE301 targets an undisclosed pathway and remains in preclinical development. The company’s pipeline is its central business, and it does not describe separate reportable business segments. It licenses candidate-related intellectual property and works with Paragon Therapeutics on antibody discovery and development. Jade Biosciences was incorporated in 2024, and its programs include candidates developed through its Paragon collaboration.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1798749
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Jade Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Jade Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Jade Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Jade Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Jade Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”